Dosing and uses of BromSite, Prolensa (bromfenac ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.07% (Prolensa)
- 0.075% (BromSite)
- 0.09% (generics)
Cataract Postoperative Ocular Inflammation/Pain
Prolensa indication: Indicated for treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction
BromSite indication: Indicated to prevent ocular pain and treat ocular inflammation in patients undergoing cataract surgery
1 gtt into affected eye(s) qDay beginning 1 day prior to surgery, continued on day of surgery and through the first 14 days postsurgery
Pediatric dosage forms and strengths
Safety and efficacy not established
BromSite, Prolensa (bromfenac ophthalmic) adverse (side) effects
Frequency not defined
Abnormal sensation in eye
Conjunctival hyperemia
Eye irriation (burning/stinging)
Eye pain
Eye pruritus
Eye redness
Headache
Iritis
Corneal erosion
Warnings
Contraindications
None listed by manufacturer
Cautions
Contains sodium sulfite which may cause allergic reactions in susceptible individuals NSAIDs may slow or delay healing
Potential for cross-sensitivity to other NSAIDs or aspirin
Interferes with platelet aggregation and may increase bleeding of ocular tissues; use caution in patients with predisposition to bleeding
Corneal effects, including keratitis, reported Remove contact lenses before application, may reinsert 10 minutes after instilling drops
Corneal adverse reactions may occur in patients with keratitis after continued use that may result in loss of vision; discontinue use in patients with evidence of corneal epithelial damage
Use caution in patients with diabetes (may be at risk of corneal adverse effects that may result in loss of vision)
Use caution in patients with complicated ocular surgeries, corneal denervation, repeat ocular surface disease, or corneal epithelial defects
Use caution in patients with rheumatoid arthritis
Pregnancy and lactation
Pregnancy category: C; D in 3rd trimester
Lactation: Excretion in milk unknown; use with caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of BromSite, Prolensa (bromfenac ophthalmic)
Mechanism of action
Nonsteroidal anti-inflammatory agent; inhibits COX-1 and COX-2, which results in decreased formation of prostaglandin precursors
Absorption
Negligible systemic absorption
Half-life: 0.5-4 hr
